Customize your JAMA Network experience by selecting one or more topics from the list below.
Tanihara and colleagues studied the short-term results of topically administered selective Rho kinase inhibitor, K-115, in a randomized, double-masked, placebo-controlled clinical trial. Fifty healthy volunteers received a single instillation, while another 50 healthy volunteers received repeated instillation of increasing concentrations in a stepwise manner. Maximal intraocular pressure reductions were noted 1 to 2 hours after instillation, with slight to mild conjunctival hyperemia found in more than half of the participants after each instillation of the drug, typically resolving within 90 minutes. These findings suggest a potential benefit of this class of medications, pending further clinical trials.
Continuing Medical Education
Highlights. JAMA Ophthalmol. 2013;131(10):1259. doi:10.1001/jamaophthalmol.2013.4136
Create a personal account or sign in to: